

MEMORANDUM

Date: November 2, 2010

From: Gil Sambrano, PhD
Senior Review Officer

To: Independent Citizen's Oversight Committee

Subject: Staff Recommendation for Early Translational II Application TR2-01857

At the October board meeting the ICOC approved funding for application TR2-01857 with modifications recommended by the Grants Working Group. The GWG recommended that the preclinical model studies, GMP cell banking and other activities not required for feasibility should be removed from this project and that the award be changed to a Development Candidate Feasibility (DCF) Award.

Approval for funding as a DCF Award instead of the original Development Candidate Award includes a limit in the direct project costs to \$1.15M and removal of the co-PI role.

However, a large proportion of the remaining activities were intended to be conducted by the co-PI and it is unclear whether those activities can be adequately carried out under the reduced budget of a DCF Award.

Staff recommends that a better way to achieve the GWG intent might be for the ICOC to approve funding at the requested amount of \$5,199,767 with the condition that preclinical model, GMP cell bank and related activities be removed, that the budget be adjusted down to reflect these changes during administrative review by CIRM staff, and that the designation of a DC or DCF Award be assigned by CIRM staff in accordance with the final budget, relative contribution of the co-PI, and expected outcome of the project.